Two industry insiders say Mylan pays no more than $30 per device, NBC News reports.
Stocks that would do well in the event of a GOP presidential victory are no longer lagging the Clinton stocks as much as they had been.
German health care group Fresenius is buying Spain's biggest private hospital chain Quironsalud for 5.8 billion euros.
The U.S. is furious at the EU for slapping Apple with a $14.5 billion tax bill but the EU say it was the U.S. that put them on to the scheme.
Jim Cramer pointed to technology, retail, food and energy groups that need takeovers in order to stay appealing.
It's not just greed that makes companies like Mylan charge outrageous prices for drugs, explains former FDA official Scott Gottlieb.
Mylan says the health-care system is to blame for families having to pay more for life-saving drugs like EpiPen and Joe Minarik says, sadly, that’s pretty much true.
The FDA and Congress enabled Mylan to secure a monopoly on EpiPens and then jack up the prices, says this intellectual-property expert. So why can't they just end it?
The "Halftime Report" traders give their final trades of the show.
Traders are loving Pfizer more, according to data showing an increase in bullish mentions of the stock on Twitter.
The "FMHR" traders reveal their final trades, including Lending Club and Amgen.
Some of the names on the move ahead of the open.
AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer in a deal that could be valued at more than $1.5 billion.
After Pfizer's $14 billion proposed acquisition of Medivation, these biotech stocks could emerge as winners, if history is any guide.
U.K. pharma giant agrees to sell its small molecule antibiotics business to Pfizer of the U.S.
Biotech is rallying, and the bounce will continue, two technical analysts say.
Debt is cheap, markets are high and bankers are expecting more big M&A to close out the year.
Pharmaceutical firms rely on acquisitions to plug the gap on innovations they do not currently possess, says Albert Fried and Company's Sachin Shah.
Pfizer investors should be concerned about the high premium, while Medivation investors should celebrate, says RBC Capital Markets' Simos Simeonidis.
Jim Cramer looked ahead to Fed Chair Janet Yellen’s speech in Jackson Hole.